These results demonstrate that variants conferring risk of BPH/LUTS and their effects on PSA levels warrant being taken into consideration when interpreting measurements of individual PSA levels, performed in order to screen for prostate cancer. This evidence concerns the gene KLK3 and Familial prostate cancer.